From each FDA label, and Medicare's and sellers' prices

GLP-1s over 65: what each FDA label says, and what it costs

Last updated

No FDA label names a best GLP-1 for people over 65. Each label has a section on people 65 and older: 10 of the 10 we read say their trials saw no overall difference between them and younger people. Zepbound's says: "No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65 years of age and older and younger adult patients." On Medicare, the GLP-1 Bridge charges $50 per 28- or 30-day fill for Wegovy, Wegovy HD, Zepbound, and Foundayo, with prior authorization. Without insurance, FDA-approved GLP-1s start at $149 per 30 days (Foundayo (LillyDirect self-pay) at LillyDirect (Eli Lilly)).

What each label says about people 65 and older

Section 8.5, Geriatric Use, of each current FDA label, word for word, with the day the label took effect.

  • Byetta

    “Population pharmacokinetic analysis of patients ranging from 22 to 73 years of age suggests that age does not influence the pharmacokinetic properties of exenatide. BYETTA was studied in 282 patients 65 years of age or older and in 16 patients 75 years of age or older. No differences in safety or effectiveness were observed between these patients and younger patients. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Sep 2, 2025

  • Foundayo

    “In a pool of Trials 1 and 2, 399 (13%) FOUNDAYO-treated patients were 65 years of age or older, and 33 (1%) FOUNDAYO-treated patients were 75 years of age or older at baseline. No overall differences in safety or effectiveness of FOUNDAYO have been observed between patients 65 years of age or older and younger adult patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Jul 29, 2026

  • Mounjaro

    “In the pool of seven clinical trials, 1,539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline. In a CV outcomes trial, 3,327 (50%) of MOUNJARO-treated patients were 65 years of age or older, and 705 (11%) of MOUNJARO-treated patients were 75 years of age or older at baseline. No overall differences in safety or effectiveness of MOUNJARO have been observed between patients 65 years of age and older and younger adult patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Aug 27, 2026

  • Ozempic

    “In the pool of placebo- and active-controlled glycemic control trials, 744 (23.6%) OZEMPIC-treated patients were 65 years of age and over and 102 OZEMPIC-treated patients (3.2%) patients were 75 years of age and over. In SUSTAIN 6, the cardiovascular outcome trial, 788 (48%) OZEMPIC-treated patients were 65 years of age and over and 157 OZEMPIC-treated patients (9.6%) patients were 75 years of age and over. No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Jun 1, 2026

  • Rybelsus and Ozempic tablets

    “In the pool of glycemic control trials, 1,229 (30%) patients treated with semaglutide tablets were 65 years of age and over and 199 (5%) patients treated with semaglutide tablets were 75 years of age and over. In Trial 8, one of the CV outcomes trials, 891 (56%) patients treated with semaglutide tablets were 65 years of age and over and 200 (13%) patients treated with semaglutide tablets were 75 years of age and over. No overall differences in safety or effectiveness for semaglutide tablets have been observed between patients 65 years of age and older and younger adult patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Jan 30, 2026

  • Saxenda

    “In the SAXENDA clinical trials, 232 (6.9%) of the SAXENDA-treated patients were 65 years of age and over, and 17 (0.5%) of the SAXENDA-treated patients were 75 years of age and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Feb 25, 2026

  • Trulicity

    “In the adult glycemic control trials, 620 (19%) of TRULICITY-treated patients were 65 years of age or older and 65 (2%) of TRULICITY-treated patients were 75 years of age or older at baseline. In the TRULICITY 1.5 mg treatment arm of the REWIND trial (cardiovascular outcomes trial in adults with type 2 diabetes mellitus and cardiovascular disease or multiple cardiovascular risk factors), 2,619 (53%) patients were 65 years of age or older, and 484 (10%) patients were 75 years of age or older at baseline. No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Jun 16, 2026

  • Victoza

    “In the VICTOZA treatment arms of the glycemic control trials, a total of 832 (19.3%) of the patients were 65 to 74 years of age and 145 (3.4%) were 75 years of age and over. In the VICTOZA treatment arm of the LEADER trial, a total of 1738 (37.2%) patients were 65 to 74 years of age, 401 (8.6%) were 75 to 84 years of age, and 17 (0.4%) were 85 years of age or older at baseline. No overall differences in safety or effectiveness for VICTOZA have been observed between patients 65 years of age and older and younger patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Oct 14, 2025

  • Wegovy

    “In the WEGOVY injection clinical trials for weight reduction and long-term maintenance, 233 (9%) WEGOVY injection-treated patients were aged 65 to less than 75 years and 23 (1%) WEGOVY injection-treated patients were aged 75 years and older. In a WEGOVY 25 mg tablets clinical trial for weight reduction and long-term maintenance, 16 (8%) WEGOVY tablets-treated patients were aged 65 to less than 75 years and 5 (2%) WEGOVY tablet-treated patients were aged 75 years and older. In a CV outcomes trial, 2,656 (30%) WEGOVY injection-treated patients were aged 65 to 75 years and 703 (8%) WEGOVY injection-treated patients were aged 75 years and older. No overall difference in the effectiveness was observed between patients aged 65 years and older and younger adult patients. In the CV outcomes trial, patients aged 75 years and older reported more hip and pelvis fractures in the WEGOVY injection-treated patients than placebo-treated patients. Patients aged 75 years and older (WEGOVY injection-treated and placebo-treated) reported more serious adverse reactions overall compared to younger adult patients. In the clinical trial in patients with MASH, of the 534 patients randomized to WEGOVY injection, 138 (26%) were aged 65 years and older and 13 (2%) were aged 75 years and older. No overall differences in safety or effectiveness of WEGOVY injection have been observed between patients 65 years of age and older and younger adult patients with MASH.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Jun 18, 2026

  • Zepbound

    “In a pool of two fixed dose ZEPBOUND clinical studies for weight reduction (Study 1 and Study 2), 226 (9%) ZEPBOUND-treated patients were 65 years of age or older, and 13 (0.5%) ZEPBOUND-treated patients were 75 years of age or older at baseline. No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65 years of age and older and younger adult patients. ZEPBOUND clinical studies in OSA (Study 5 and Study 6) did not include sufficient numbers of patients age 65 years or older to determine whether they respond differently from younger adult patients. Other reported clinical experience with tirzepatide has not identified differences in responses between the elderly and younger patients.”

    FDA label on DailyMed (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm), effective Aug 28, 2026

What Medicare pays

Medicare's GLP-1 Bridge, as CMS states it.

$50 per 28- or 30-day fill for Wegovy, Wegovy HD, Zepbound, Foundayo. For eligible Part D enrollees using a covered product for weight management, with prior authorization. Bridge operates outside the Part D benefit. Its copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply.

CMS program details (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge)

Common questions

What is the best GLP-1 for someone over 65?

No FDA label ranks them for older adults. 10 of the 10 labels say their trials found no overall difference between people 65 and older and younger people. What differs is what each is approved for, how it is taken and what it costs, which a prescriber weighs with the person's other medicines and conditions. Each medicine, what it is approved for

Are GLP-1s safe for people over 65?

The labels speak to it in their section on older people. Zepbound's says: "No overall differences in safety or effectiveness of ZEPBOUND have been observed between patients 65 years of age and older and younger adult patients." Each label's warnings apply at every age, and some labels add advice for older people in that section; each is quoted below. Side effects, from each label

Is a GLP-1 safe for women over 65?

The labels' sections on older people do not split by sex. The few figures the labels give by sex are on the side effects page for women and men. Side effects in women and men

Does Medicare pay for GLP-1s for weight loss?

Through the GLP-1 Bridge, $50 per 28- or 30-day fill for Wegovy, Wegovy HD, Zepbound, and Foundayo. CMS: For eligible Part D enrollees using a covered product for weight management, with prior authorization. Bridge operates outside the Part D benefit. Its copay does not count toward Part D out-of-pocket spending, and the Part D deductible does not apply. Who qualifies and how to get it

What does a GLP-1 cost without insurance?

FDA-approved GLP-1s start at $149 per 30 days at the starting dose (Foundayo (LillyDirect self-pay) at LillyDirect (Eli Lilly)). Prices rise with the dose at most sellers, and every price is dated on the price pages. The cheapest GLP-1s, dated

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.